Travere Therapeutics Q2 2024 Adj. EPS $(0.65) Beats $(0.86) Estimate, Sales $52.176M Beat $50.169M Estimate
Author: Benzinga Newsdesk | August 01, 2024 04:49pm
Travere Therapeutics (NASDAQ:
TVTX) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.86) by 24.42 percent. This is a 17.72 percent increase over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $52.176 million which beat the analyst consensus estimate of $50.169 million by 4.00 percent. This is a 12.60 percent decrease over sales of $59.697 million the same period last year.
Posted In: TVTX